---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-098474"
form_type: "8-K"
ticker: "DSGN"
cik: "0001807120"
company_name: "Design Therapeutics, Inc."
filed_at: "2026-03-09T23:59:59+00:00"
generated_at: "2026-05-15T18:06:34.098195+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Design Therapeutics reports Q4 2025 net loss of $16.0M; cash $219.8M funds operations into 2029

## Summary
- Full-year 2025 net loss $69.8M; R&D expenses $59.1M, G&A $20.3M.
- Cash, equivalents and securities $219.8M as of Dec 31, 2025; runway into 2029.
- DT-216P2 (FA) RESTORE-FA trial ongoing; frataxin data expected H2 2026.
- DT-168 (FECD) Phase 2 biomarker trial data anticipated H2 2026.
- DT-818 (DM1) Phase 1 MAD trial dosing expected H1 2026; results in 2027.

## SEC filing metadata
- accession: 0001193125-26-098474
- form_type: 8-K
- ticker: DSGN
- cik: 0001807120
- company_name: Design Therapeutics, Inc.
- filed_at: 2026-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1807120/000119312526098474/0001193125-26-098474-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1807120/000119312526098474/dsgn-20260309.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-098474
- JSON: https://secwatch.observer/filing/0001193125-26-098474.json
- Plain text: https://secwatch.observer/filing/0001193125-26-098474.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.